Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
about
Novel targets in the treatment of advanced gastric cancer: a perspective reviewUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicPrevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.The c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer.
P2860
Q26765208-9AC2AF42-6544-47DE-A985-635A01A4695AQ28071541-7686A5A0-DE6E-4861-9637-335CD483C768Q38600659-C9DAD455-5B2B-4375-B9E7-AAA7607C12F3Q38645200-D440465C-64DA-4AE3-A558-174D9697BFAEQ38747875-F48934D4-218D-4AF9-AD25-808776A7C037Q41184434-A7BE5803-CD74-4676-904E-452BB1BD3F1BQ46270437-B9F7BCED-5183-4ACB-B2D1-D8D8008804BAQ47140946-AB81222A-93C9-4DB1-89D5-837D9A49D0D5Q47584566-17188D88-3876-4F28-A9DA-C4CB780E67E5Q48365186-8C1C60C0-2414-4CF8-98CB-535FB7A4DD95Q52607320-16A8688A-71F7-42EB-8150-E248CB01D27AQ55431246-D1BFB6C2-63DC-428E-B9C9-4B84C98B5EA8
P2860
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pan-cancer analysis of genomic ...... ions for existing cancer drugs
@en
type
label
Pan-cancer analysis of genomic ...... ions for existing cancer drugs
@en
prefLabel
Pan-cancer analysis of genomic ...... ions for existing cancer drugs
@en
P2093
P2860
P50
P1433
P1476
Pan-cancer analysis of genomic ...... ions for existing cancer drugs
@en
P2093
Andrea L Richardson
Daniel P Silver
Tejal Joshi
Zhigang C Wang
P2860
P2888
P356
10.1186/S40364-015-0033-4
P50
P577
2015-05-01T00:00:00Z
P5875
P6179
1009248978